Efficacy, Safety and JC-Antibody Prevalence Following Natalizumab Treatment for 36 Month and More in Patients with Relapsing Remitting Multiple Sclerosis (P02.135)
medicine.medical_specialty Natalizumab Relapsing remitting business.industry Multiple sclerosis Internal medicine Medicine In patient Neurology (clinical) business Antibody prevalence medicine.disease medicine.drug